In systemic sclerosis (SSc), CD19 CAR-T has been linked to approximately 80% improvement in modified Rodnan skin score (mRSS) in Phase II, possibly by modulating innate immune responses, reducing NK-cell exhaustion, and lowering Scl-70 immune complexes [368, 371]. The gene discussed is CD19; the disease is systemic sclerosis.